AR047669A1 - Entidad seleccionada entre un compuesto de xantina y un derivado fisiologicamente funcional del mismo, su uso para la fabricacion de un medicamento, formulacion farmaceutica y combinacion de formulaciones que la comprenden y metodo para su preparacion - Google Patents
Entidad seleccionada entre un compuesto de xantina y un derivado fisiologicamente funcional del mismo, su uso para la fabricacion de un medicamento, formulacion farmaceutica y combinacion de formulaciones que la comprenden y metodo para su preparacionInfo
- Publication number
- AR047669A1 AR047669A1 ARP050100512A ARP050100512A AR047669A1 AR 047669 A1 AR047669 A1 AR 047669A1 AR P050100512 A ARP050100512 A AR P050100512A AR P050100512 A ARP050100512 A AR P050100512A AR 047669 A1 AR047669 A1 AR 047669A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- alkyl
- different
- propyl
- manufacture
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 208000000103 Anorexia Nervosa Diseases 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010070901 Diabetic dyslipidaemia Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 101000843809 Homo sapiens Hydroxycarboxylic acid receptor 2 Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 102100030643 Hydroxycarboxylic acid receptor 2 Human genes 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N Xanthine Natural products O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 229940075420 xanthine Drugs 0.000 abstract 1
- -1 xanthine compound Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0403282A GB0403282D0 (en) | 2004-02-14 | 2004-02-14 | Chemical compounds |
| GB0423562A GB0423562D0 (en) | 2004-10-22 | 2004-10-22 | Novel compounds |
| GB0428375A GB0428375D0 (en) | 2004-12-24 | 2004-12-24 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR047669A1 true AR047669A1 (es) | 2006-02-01 |
Family
ID=34864831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050100512A AR047669A1 (es) | 2004-02-14 | 2005-02-14 | Entidad seleccionada entre un compuesto de xantina y un derivado fisiologicamente funcional del mismo, su uso para la fabricacion de un medicamento, formulacion farmaceutica y combinacion de formulaciones que la comprenden y metodo para su preparacion |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US7713982B2 (enExample) |
| EP (1) | EP1781657B1 (enExample) |
| JP (2) | JP5001012B2 (enExample) |
| KR (1) | KR101100601B1 (enExample) |
| CN (2) | CN101863888B (enExample) |
| AR (1) | AR047669A1 (enExample) |
| AU (1) | AU2005212816C1 (enExample) |
| BR (1) | BRPI0507604A (enExample) |
| CA (1) | CA2556073C (enExample) |
| CY (1) | CY1114022T1 (enExample) |
| DK (1) | DK1781657T3 (enExample) |
| ES (1) | ES2406732T3 (enExample) |
| HR (1) | HRP20130406T1 (enExample) |
| IL (1) | IL177051A (enExample) |
| MA (1) | MA28357A1 (enExample) |
| MY (1) | MY148937A (enExample) |
| NO (1) | NO337281B1 (enExample) |
| NZ (1) | NZ548496A (enExample) |
| PE (1) | PE20060317A1 (enExample) |
| PL (1) | PL1781657T3 (enExample) |
| PT (1) | PT1781657E (enExample) |
| SG (1) | SG157242A1 (enExample) |
| SI (1) | SI1781657T1 (enExample) |
| TW (1) | TWI350289B (enExample) |
| WO (1) | WO2005077950A2 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL206890B1 (pl) * | 1999-11-12 | 2010-10-29 | Biogen Idec Ma | Pochodna bicykloalkilopuryny, jej zastosowanie i kompozycja leku |
| AR039385A1 (es) | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
| EP1603585A2 (en) | 2003-03-14 | 2005-12-14 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74 |
| PE20050483A1 (es) | 2003-10-31 | 2005-08-25 | Arena Pharm Inc | Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas |
| SI1781657T1 (sl) * | 2004-02-14 | 2013-07-31 | Glaxosmithkline Intellectual Property Development Limited | Zdravila z aktivnostjo na receptor hm74a |
| NZ555320A (en) | 2004-12-03 | 2010-11-26 | Schering Corp | Substituted piperazines as CB1 antagonists |
| MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
| PE20060949A1 (es) | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
| AU2006247695B2 (en) | 2005-05-17 | 2012-08-09 | Merck Sharp & Dohme Corp. | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia |
| US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| US7750015B2 (en) | 2005-05-17 | 2010-07-06 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| AU2006259137B2 (en) * | 2005-06-14 | 2010-04-01 | F. Hoffmann-La Roche Ag | Anthranilic acid derivatives |
| HRP20110295T1 (hr) | 2005-06-28 | 2011-05-31 | Merck Sharp & Dohme Corp. | Agonisti receptora niacina, smjese koje sadržavaju takve spojeve i postupci liječenja |
| EP1912992A1 (en) * | 2005-08-10 | 2008-04-23 | SmithKline Beecham Corporation | Xanthine derivatives as selective hm74a agonists |
| CN101400682A (zh) * | 2006-01-20 | 2009-04-01 | 先灵公司 | 治疗异常脂血症的杂环烟酸受体激动剂 |
| MX2008014689A (es) * | 2006-05-23 | 2008-11-27 | Hoffmann La Roche | Derivados de piridopirimidininona. |
| TW200804383A (en) | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
| CA2656039A1 (en) | 2006-06-23 | 2007-12-27 | Incyte Corporation | Purinone derivatives as hm74a agonists |
| AR061626A1 (es) | 2006-06-23 | 2008-09-10 | Incyte Corp | Derivados de purinona como agonistas de hm74a |
| CA2680775A1 (en) | 2007-03-23 | 2008-10-02 | F. Hoffmann-La Roche Ag | Aza-pyridopyrimidinone derivatives |
| PL2370440T3 (pl) * | 2008-12-08 | 2015-05-29 | Glaxosmithkline Llc | Bezwodnik 2-amino-2-(hydroksymetylo)-1,3-propanodiolu 8-chloru-3-pentylo-3,7-dihydro-1H-puryno-2,6-dionu do leczenia chorób |
| WO2010075069A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
| EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
| CN102276610B (zh) * | 2011-05-04 | 2013-01-09 | 北京工业大学 | N7-鸟嘌呤烷化物的制备方法 |
| CN103360394B (zh) * | 2013-07-29 | 2015-07-22 | 上海万巷制药有限公司 | 8-氯茶碱的制备方法 |
| BR112017016065A2 (pt) * | 2015-01-30 | 2018-04-03 | Shanton Pharma Co., Ltd. | prevenção ou tratamento de ácido úrico ou doença gotosa |
| CN104892610B (zh) * | 2015-05-27 | 2016-08-24 | 福建师范大学 | 一种8-酯基咖啡因衍生物的制备方法 |
| CN105622610A (zh) * | 2016-03-28 | 2016-06-01 | 浙江诚意药业股份有限公司 | 一种黄嘌呤化合物的制备方法 |
| WO2018019911A1 (en) | 2016-07-27 | 2018-02-01 | Hartis-Pharma Sarl | Therapeutic combinations to treat red blood cell disorders |
| CN106632061B (zh) * | 2016-11-23 | 2020-07-24 | 上海皓元医药股份有限公司 | 一种1-(4-苯基-1-烷基-1h-咪唑-2-基)乙酮及其衍生物的合成方法 |
| MX2019008230A (es) | 2017-01-10 | 2019-10-24 | Bayer Ag | Derivados heterociclicos como agentes de control de plagas. |
| JP2022549807A (ja) * | 2019-09-25 | 2022-11-29 | ゴールドフィンチ バイオ，インク． | キサンチンｃｂ１阻害物質 |
| CN112724141A (zh) * | 2021-01-21 | 2021-04-30 | 南京艾美斐生物医药科技有限公司 | 一种gpr109a蛋白受体抑制剂及其制备和应用 |
| CN113262882B (zh) * | 2021-07-21 | 2021-09-17 | 北京矿冶研究总院 | 阳离子捕收剂、制备方法及在磷矿反浮选中的应用 |
| AU2024229006A1 (en) * | 2023-02-27 | 2025-09-18 | Shanton Pharma Pte. Ltd. | Crystal form of 8-chloro-3-pentyl-3,7-dihydro-1h-purin-2,6-dione compound and preparation method therefor |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2797220A (en) * | 1954-12-02 | 1957-06-25 | Univ Michigan | Substituted paraxanthines |
| US4847377A (en) * | 1985-05-13 | 1989-07-11 | Schering Corporation | Substituted-2,3-dihydro-6-substituted-pyrimido[2,1-F]-purine-4,8(1H,9H)-diones |
| GB8906792D0 (en) * | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
| NZ240644A (en) * | 1990-11-21 | 1994-08-26 | Smithkline Beecham Corp | Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf) |
| WO1993016699A1 (en) * | 1992-02-21 | 1993-09-02 | Smithkline Beecham Corporation | Tnf inhibitors |
| ATE230990T1 (de) | 1992-03-04 | 2003-02-15 | Cell Therapeutics Inc | Enantiomere hydroxylierte xanthinverbindungen |
| US5473070A (en) | 1992-11-16 | 1995-12-05 | Cell Therapeutics, Inc. | Substituted long chain alcohol xanthine compounds |
| US6693105B1 (en) * | 1992-11-16 | 2004-02-17 | Cell Therapeutics, Inc. | Hydroxyl-containing compounds |
| US6469017B1 (en) * | 1998-01-16 | 2002-10-22 | Cell Therapeutics, Inc. | Method of inhibiting interleukin-12 signaling |
| US5804584A (en) | 1992-11-16 | 1998-09-08 | Cell Therapeutics, Inc. | Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms |
| IL109161A0 (en) | 1993-03-31 | 1994-06-24 | Cell Therapeutics Inc | Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same |
| US5670506A (en) | 1993-04-05 | 1997-09-23 | Cell Therapeutics, Inc. | Halogen, isothiocyanate or azide substituted xanthines |
| AU6702894A (en) | 1993-04-09 | 1994-11-08 | Cell Therapeutics, Inc. | Ring-substituted cell signaling inhibitors |
| AU1868195A (en) | 1994-01-28 | 1995-08-15 | Cell Therapeutics, Inc. | Cell signaling inhibitors |
| EP0746557A4 (en) * | 1994-02-18 | 1997-05-02 | Cell Therapeutics Inc | INTRACELLULAR SIGNALING MEDIATORS |
| US6780865B1 (en) | 1994-02-18 | 2004-08-24 | Cell Therapeutics, Inc. | Compounds having selective hydrolytic potentials |
| US6878715B1 (en) * | 1994-02-18 | 2005-04-12 | Cell Therapeutics, Inc. | Therapeutic compounds for inhibiting interleukin-12 signals and method for using same |
| US6103730A (en) * | 1994-03-24 | 2000-08-15 | Cell Therapeutics, Inc. | Amine substituted compounds |
| US5807861A (en) * | 1994-03-24 | 1998-09-15 | Cell Therapeutics, Inc. | Amine substituted xanthinyl compounds |
| US5801182A (en) | 1994-03-24 | 1998-09-01 | Cell Therapeutics, Inc. | Amine substituted compounds |
| US6323201B1 (en) | 1994-12-29 | 2001-11-27 | The Regents Of The University Of California | Compounds for inhibition of ceramide-mediated signal transduction |
| AR015966A1 (es) * | 1997-10-17 | 2001-05-30 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito |
| JP2002541258A (ja) | 1999-04-09 | 2002-12-03 | セル セラピューティクス インコーポレーテッド | インターリューキン−１２シグナルを阻害するための治療用化合物及びその使用方法 |
| US20030207901A1 (en) * | 1999-07-27 | 2003-11-06 | Cell Therapeutics, Inc. | Hydroxyl-containing compounds |
| KR100502757B1 (ko) * | 1999-08-31 | 2005-07-22 | 반더빌트유니버시티 | Ａ２ｂ 아데노신 수용체의 선택적인 길항제 |
| EP1305328A2 (en) * | 2000-07-21 | 2003-05-02 | Mark B. Lyles | Materials and methods for binding nucleic acids to surfaces |
| FR2812482B1 (fr) * | 2000-07-28 | 2003-01-24 | Inside Technologies | Dispositif electronique portable comprenant plusieurs circuits integres sans contact |
| JP2004512278A (ja) * | 2000-09-19 | 2004-04-22 | ノビムーヌ ソシエテ アノニム | 新規な免疫調節剤、免疫阻害剤、及び抗炎症剤としてのスタチン（ＨＭＧ−ＣｏＡリダクターゼ阻害剤） |
| US6821978B2 (en) | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
| HU230384B1 (hu) * | 2001-02-24 | 2016-03-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xantinszármazékok, előállításuk és alkalmazásuk gyógyszerként |
| US20040254224A1 (en) * | 2001-04-11 | 2004-12-16 | Foord Steven Michael | Medicaments |
| SI1781657T1 (sl) | 2004-02-14 | 2013-07-31 | Glaxosmithkline Intellectual Property Development Limited | Zdravila z aktivnostjo na receptor hm74a |
| US20090209561A1 (en) * | 2004-10-22 | 2009-08-20 | Richard Jonathan Daniel Hatley | Xanthine Derivatives with HM74A Receptor Activity |
| WO2006045564A1 (en) | 2004-10-22 | 2006-05-04 | Smithkline Beecham Corporation | Xanthine derivatives with hm74a receptor activity |
| EP1912992A1 (en) | 2005-08-10 | 2008-04-23 | SmithKline Beecham Corporation | Xanthine derivatives as selective hm74a agonists |
| EP1939197A1 (en) * | 2006-12-22 | 2008-07-02 | Schwarz Pharma Ag | 8-ethinylxanthine derivatives as selective A2A receptor antagonists |
| PL2370440T3 (pl) * | 2008-12-08 | 2015-05-29 | Glaxosmithkline Llc | Bezwodnik 2-amino-2-(hydroksymetylo)-1,3-propanodiolu 8-chloru-3-pentylo-3,7-dihydro-1H-puryno-2,6-dionu do leczenia chorób |
| US20110065676A1 (en) * | 2009-06-24 | 2011-03-17 | Schering Corporation | Combination therapies comprising par1 antagonists with nar agonists |
-
2005
- 2005-02-10 SI SI200531730T patent/SI1781657T1/sl unknown
- 2005-02-10 WO PCT/EP2005/001449 patent/WO2005077950A2/en not_active Ceased
- 2005-02-10 ES ES05707363T patent/ES2406732T3/es not_active Expired - Lifetime
- 2005-02-10 NZ NZ548496A patent/NZ548496A/en not_active IP Right Cessation
- 2005-02-10 AU AU2005212816A patent/AU2005212816C1/en not_active Ceased
- 2005-02-10 SG SG200803771-5A patent/SG157242A1/en unknown
- 2005-02-10 KR KR1020067016277A patent/KR101100601B1/ko not_active Expired - Fee Related
- 2005-02-10 BR BRPI0507604-8A patent/BRPI0507604A/pt not_active Application Discontinuation
- 2005-02-10 EP EP05707363A patent/EP1781657B1/en not_active Expired - Lifetime
- 2005-02-10 DK DK05707363.7T patent/DK1781657T3/da active
- 2005-02-10 CN CN2010102007350A patent/CN101863888B/zh not_active Expired - Fee Related
- 2005-02-10 HR HRP20130406TT patent/HRP20130406T1/hr unknown
- 2005-02-10 PL PL05707363T patent/PL1781657T3/pl unknown
- 2005-02-10 CA CA2556073A patent/CA2556073C/en not_active Expired - Fee Related
- 2005-02-10 JP JP2006552565A patent/JP5001012B2/ja not_active Expired - Fee Related
- 2005-02-10 CN CN2005800114336A patent/CN101103030B/zh not_active Expired - Fee Related
- 2005-02-10 PT PT57073637T patent/PT1781657E/pt unknown
- 2005-02-10 US US10/589,474 patent/US7713982B2/en not_active Expired - Fee Related
- 2005-02-11 PE PE2005000170A patent/PE20060317A1/es not_active Application Discontinuation
- 2005-02-14 TW TW094104133A patent/TWI350289B/zh not_active IP Right Cessation
- 2005-02-14 AR ARP050100512A patent/AR047669A1/es not_active Application Discontinuation
- 2005-02-14 MY MYPI20050527A patent/MY148937A/en unknown
-
2006
- 2006-07-24 IL IL177051A patent/IL177051A/en not_active IP Right Cessation
- 2006-08-11 MA MA29262A patent/MA28357A1/fr unknown
- 2006-09-13 NO NO20064151A patent/NO337281B1/no not_active IP Right Cessation
-
2008
- 2008-02-12 JP JP2008030344A patent/JP5020848B2/ja not_active Expired - Fee Related
-
2009
- 2009-09-02 US US12/552,649 patent/US8394808B2/en not_active Expired - Fee Related
-
2010
- 2010-03-04 US US12/717,349 patent/US8268839B2/en not_active Expired - Fee Related
-
2013
- 2013-02-06 US US13/760,423 patent/US20130150383A1/en not_active Abandoned
- 2013-05-29 CY CY20131100430T patent/CY1114022T1/el unknown
-
2014
- 2014-11-21 US US14/549,721 patent/US20150080418A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR047669A1 (es) | Entidad seleccionada entre un compuesto de xantina y un derivado fisiologicamente funcional del mismo, su uso para la fabricacion de un medicamento, formulacion farmaceutica y combinacion de formulaciones que la comprenden y metodo para su preparacion | |
| JP2007522176A5 (enExample) | ||
| Ahrén et al. | Mechanisms of action of the dipeptidyl peptidase‐4 inhibitor vildagliptin in humans | |
| HRP20100725T1 (hr) | Derivati ksantina kao selektivni agonisti hm74a | |
| CO5621286A2 (es) | Combinacion de un inhibidor de dpp iv y un compuesto cardiovascular | |
| JP2020045362A5 (enExample) | ||
| ECSP045103A (es) | Compuestos heterociclicos y metodos de uso | |
| BRPI0416627A (pt) | combinação de compostos orgánicos | |
| BR112022013150A2 (pt) | Derivado da insulina | |
| JP2014516702A5 (enExample) | ||
| RU2012100397A (ru) | Препарат, содержащий инсулин, никотинамид и аминокислоту | |
| JP2015517459A5 (enExample) | ||
| HRP20120029T1 (hr) | Derivati (4(4-[6-trifluorometil-piridin-3-ilamino)-n-sadržavajući-heteroaril]-fenil)-cikloheksil)-octene kiseline i njihove farmaceutske uporabe | |
| ECSP056175A (es) | Heterociclos de nitrógeno n-acilo como ligandos de receptores activados por el proliferador de peroxisoma | |
| MY193993A (en) | Fatty acids and their use in conjugation to biomolecules | |
| EA200970360A1 (ru) | Омега-3 жирные кислоты и средство для лечения дислипидемии для снижения уровней аро-в | |
| JP2015503539A5 (enExample) | ||
| BRPI0818687A2 (pt) | composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença. | |
| NO20084919L (no) | Oksadiazolidindionforbindelse | |
| MX2015013893A (es) | Nuevo derivado de acido 3-(4-(benciloxi)fenil)hex-4-inoico, metodo de preparacion del mismo y composicion farmaceutica para la prevencion y tratamiento de la enfermedad metabolica que incluye el mismo como ingrediente activo. | |
| JP2019531320A5 (enExample) | ||
| BRPI0516446A (pt) | combinação de compostos orgánicos | |
| BRPI0407180A (pt) | Composto, composição farmacêutica, métodos para modular um receptor ativado pelo proliferador de peroxissoma, para tratar ou prevenir uma doença ou condição, para diminuir a glicose no sangue em um mamìfero, para tratar ou prevenir diabetes mellitus, doença cardiovascular e sìndrome x em um mamìfero, e, uso de um composto | |
| AR063095A1 (es) | Antagonistas del receptor de trombina basados en la unidad triciclica modificada de himbacina | |
| US20080009503A1 (en) | Method of treating diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed, e.g., due to non-payment of fee |